Acerus Pharmaceuticals Corp (ASP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Acerus Pharmaceuticals Corp (ASP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9950
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation develops, manufactures, markets and distributes novel innovative branded products. It focuses on providing men’s and women’s health. The company uses its proprietary drug delivery technology platforms, which include a bioadhesive nasal gel and the TriVair Deposition/Dispersion System, for the delivery of its products. Its product portfolio includes Estrace, which is approved in Canada for relief from menopausal symptoms; and Natesto, a testosterone nasal gel, which is approved by the US FDA for the treatment of male hypogonadism and filed for approval in Canada. Acerus is also developing Tefina (testosterone nasal gel) for women with female sexual dysfunction. Acerus is headquartered in Mississauga, Ontario, Canada.

Acerus Pharmaceuticals Corp (ASP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2012 to YTD 2018 10
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 13
Partnerships 15
Trimel Pharma Enters Into Co-Development Agreement With European Company 15
Licensing Agreements 16
Acerus Pharma Enters into Licensing Agreement with Pharmanest 16
Producto Cientificos Enters into Licensing Agreement with Acerus Pharma 17
Acerus Pharma Enters into Distributor and Licensing Agreement with Metuchen Pharma 18
Acerus Pharma Enters into Licensing Agreement with Viramal 19
Apsen Farmaceutica Enters into Licensing Agreement with Acerus Pharma 20
Eu Hwa Enters into Licensing Agreement with Acerus Pharma for NATESTO 21
medac Enters into Licensing Agreement with Acerus Pharma for NATESTO 22
Therios Healthcare Enters into Licensing Agreement with Acerus Pharma for NATESTO 23
Aytu BioScience Enters into Licensing Agreement with Acerus Pharma 24
Acerus Pharma Enters into Licensing Agreement with Medinova 25
Acerus Pharma Enters into Licensing and Distribution Agreement with Innovus Pharma 26
Equity Offering 27
Acerus Pharma Raises USD5.1 Million in Private Placement of Units 27
Acerus Pharma Raises USD2 Million in Private Placement of Shares 29
Trimel Pharma Raises USD16.6 Million in Private Placement of Shares 30
Acerus Pharma Raises USD2.1 Million in Private Placement of Shares 31
Trimel Pharma Announces Full Exercise Of Underwriter’s Option For Public Offering Of Shares For US$45 Million 32
Trimel Pharma Announces Rights Offering Of Shares 34
Trimel Pharma Completes Public Offering Of Units For US$13 Million 35
Debt Offering 37
Trimel Pharma Raises USD25 Million in Private Placement of 9.5% Convetible Note Due 2015 37
Acerus Pharmaceuticals Corp – Key Competitors 38
Acerus Pharmaceuticals Corp – Key Employees 39
Acerus Pharmaceuticals Corp – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Aug 13, 2018: Acerus Reports second quarter 2018 financial results 41
May 15, 2018: Acerus Reports First Quarter 2018 Financial Results 44
Nov 07, 2017: Acerus Reports Third Quarter 2017 Financial Results 46
Aug 11, 2017: Acerus Reports Second Quarter 2017 Financial Results 48
Mar 08, 2017: Acerus Reports Fourth Quarter and Full Year 2016 Financial Results 50
Corporate Communications 52
Jun 05, 2018: Acerus Announces Resignation Of Luc Mainville As Director 52
Mar 29, 2018: Acerus Announces Executive Leadership Change 53
Dec 07, 2017: Acerus Appoints Mr. Mark Lievonen to its Board of Directors 54
Oct 02, 2017: Acerus Announces Executive Leadership Change 55
May 05, 2017: Acerus Announces Appointment of Ken Yoon as Chief Financial Officer 56
Legal and Regulatory 57
Apr 10, 2018: Acerus Announces Settlement of Melnyk Litigation 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acerus Pharmaceuticals Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2012 to YTD 2018 10
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 13
Trimel Pharma Enters Into Co-Development Agreement With European Company 15
Acerus Pharma Enters into Licensing Agreement with Pharmanest 16
Producto Cientificos Enters into Licensing Agreement with Acerus Pharma 17
Acerus Pharma Enters into Distributor and Licensing Agreement with Metuchen Pharma 18
Acerus Pharma Enters into Licensing Agreement with Viramal 19
Apsen Farmaceutica Enters into Licensing Agreement with Acerus Pharma 20
Eu Hwa Enters into Licensing Agreement with Acerus Pharma for NATESTO 21
medac Enters into Licensing Agreement with Acerus Pharma for NATESTO 22
Therios Healthcare Enters into Licensing Agreement with Acerus Pharma for NATESTO 23
Aytu BioScience Enters into Licensing Agreement with Acerus Pharma 24
Acerus Pharma Enters into Licensing Agreement with Medinova 25
Acerus Pharma Enters into Licensing and Distribution Agreement with Innovus Pharma 26
Acerus Pharma Raises USD5.1 Million in Private Placement of Units 27
Acerus Pharma Raises USD2 Million in Private Placement of Shares 29
Trimel Pharma Raises USD16.6 Million in Private Placement of Shares 30
Acerus Pharma Raises USD2.1 Million in Private Placement of Shares 31
Trimel Pharma Announces Full Exercise Of Underwriter's Option For Public Offering Of Shares For US$45 Million 32
Trimel Pharma Announces Rights Offering Of Shares 34
Trimel Pharma Completes Public Offering Of Units For US$13 Million 35
Trimel Pharma Raises USD25 Million in Private Placement of 9.5% Convetible Note Due 2015 37
Acerus Pharmaceuticals Corp, Key Competitors 38
Acerus Pharmaceuticals Corp, Key Employees 39
Acerus Pharmaceuticals Corp, Subsidiaries 40

List of Figures
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Acerus Pharmaceuticals Corp (ASP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Robert Walters Plc (RWA):企業の財務・戦略的SWOT分析
    Summary Robert Walters Plc (Robert Walters) is a recruitment and consultancy service provider. The company offers placements of professionals on permanent, contract and interim positions. It provides recruitment services for accountancy and finance, banking and financial services, executive search, …
  • Yamato Holdings Co., Ltd.:企業の戦略・SWOT・財務情報
    Yamato Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Yamato Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Macquarie Group Ltd:企業の戦略・SWOT・財務情報
    Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Agility Public Warehousing Co:企業の戦略・SWOT・財務情報
    Agility Public Warehousing Co - Strategy, SWOT and Corporate Finance Report Summary Agility Public Warehousing Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Hosken Consolidated Investments Ltd (HCI):企業の財務・戦略的SWOT分析
    Hosken Consolidated Investments Ltd (HCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Deere & Company:企業の戦略・SWOT・財務情報
    Deere & Company - Strategy, SWOT and Corporate Finance Report Summary Deere & Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Fuji Electric Co Ltd (6504):企業の財務・戦略的SWOT分析
    Fuji Electric Co Ltd (6504) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • The Federal Bank Limited:企業の戦略・SWOT・財務分析
    The Federal Bank Limited - Strategy, SWOT and Corporate Finance Report Summary The Federal Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Goldin Financial Holdings Ltd:企業の戦略・SWOT・財務情報
    Goldin Financial Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Goldin Financial Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Smrt Corporation Ltd.:企業の戦略・SWOT・財務分析
    Smrt Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Smrt Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • BBA Aviation plc:企業の戦略・SWOT・財務情報
    BBA Aviation plc - Strategy, SWOT and Corporate Finance Report Summary BBA Aviation plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Trusted Media Brands Inc:企業の戦略的SWOT分析
    Trusted Media Brands Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Fortune Brands Home & Security Inc:企業の戦略・SWOT・財務分析
    Fortune Brands Home & Security Inc - Strategy, SWOT and Corporate Finance Report Summary Fortune Brands Home & Security Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Global Telecom Holding SAE:企業の戦略的SWOT分析
    Global Telecom Holding SAE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Alibaba Group Holding Ltd (BABA):企業の財務・戦略的SWOT分析
    Alibaba Group Holding Ltd (BABA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Koninklijke Vopak NV (VPK):石油・ガス:M&Aディール及び事業提携情報
    Summary Koninklijke Vopak NV (Vopak) is an independent tank storage company that stores and handles liquid oil products, chemicals, vegetable oils, biofuels and liquefied natural gases. It also offers logistics services, handles customs formalities and documentation for its customers at its terminal …
  • Capital City Bank Group Inc:企業の戦略・SWOT・財務分析
    Capital City Bank Group Inc - Strategy, SWOT and Corporate Finance Report Summary Capital City Bank Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • PT Bio Farma:製薬・医療:M&Aディール及び事業提携情報
    Summary PT Bio Farma (Bio Farma) is a manufacturer and supplier of vaccines, sera, and biological and diagnostics products. The company offers products such as DTP-hep B vaccine, DTP vaccine, DT vaccine, TT vaccine, polio vaccine, measles vaccine and BCG vaccine. It also offers biott vaccine for the …
  • Fortitech Inc.:戦略・SWOT・企業財務分析
    Fortitech Inc. - Strategy, SWOT and Corporate Finance Report Summary Fortitech Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Divi’s Laboratories Ltd (DIVISLAB):企業の財務・戦略的SWOT分析
    Divi's Laboratories Ltd (DIVISLAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆